Viewing StudyNCT02130193



Ignite Creation Date: 2024-05-06 @ 2:49 AM
Last Modification Date: 2024-10-26 @ 11:23 AM
Study NCT ID: NCT02130193
Status: COMPLETED
Last Update Posted: 2017-07-02
First Post: 2013-12-19

Brief Title: Investigation of Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Sponsor: GlaxoSmithKline
Organization: GlaxoSmithKline

Conditions & Keywords Data

Conditions:
Name
Pulmonary Disease Chronic Obstructive
Keywords:
Name View
PD View
Efficacy View
Danirixin View
EXACT-PRO View
COPD View
Safety View
RD View
CXCR2 inhibitor View
EXACT-RS View
PK View
HCRU exacerbations View